ArticleCell proliferation2012
BIX-01294 treatment blocks cell proliferation, migration and contractility in ovine foetal pulmonary arterial smooth muscle cells.
Article in Cell proliferation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.Pharmacology & therapeutics · 2019Pooled it
- Rewriting the vascular script: epigenetic modifiers as scribes of metabolic reprogramming in pulmonary hypertension.Journal of molecular medicine (Berlin, Germany) · 2025Review
- SETD2 drives METTL14-mediated mCellular and molecular life sciences : CMLS · 2025Article
- Review
- Exploring the pathogenesis of pulmonary vascular disease.Frontiers in medicine · 2024Review
- BACH1 deficiency prevents neointima formation and maintains the differentiated phenotype of vascular smooth muscle cells by regulating chromatin accessibility.Nucleic acids research · 2023Article
- Integrating epigenetics and metabolomics to advance treatments for pulmonary arterial hypertension.Biochemical pharmacology · 2022Review
- Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension.Biomedicines · 2022Review
- Histone methylation and vascular biology.Clinical epigenetics · 2020Review
- G9a Suppression Alleviates Corneal Neovascularization through Blocking Nox4-Mediated Oxidative Stress.Oxidative medicine and cellular longevity · 2020Article
- Epigenetic Regulation of Vascular Smooth Muscle Cells by Histone H3 Lysine 9 Dimethylation Attenuates Target Gene-Induction by Inflammatory Signaling.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.Journal of computer-aided molecular design · 2018Article
- Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension.Frontiers in pharmacology · 2018Review
- Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.Frontiers in pharmacology · 2018Article
- Critical effects of epigenetic regulation in pulmonary arterial hypertension.Cellular and molecular life sciences : CMLS · 2017Review
- Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.Oncotarget · 2017Article
- G9a histone methyltransferase inhibitor BIX01294 promotes expansion of adult cardiac progenitor cells without changing their phenotype or differentiation potential.Cell proliferation · 2016Article
- Effect of BIX-01294 on H3K9me2 levels and the imprinted gene Snrpn in mouse embryonic fibroblast cells.Bioscience reports · 2015Article
- Functional Role of G9a Histone Methyltransferase in Cancer.Frontiers in immunology · 2015Review
- The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveRecent studies have indicated a role of epigenetic phenomena in pathogenesis of pulmonary hypertension, but in foetal pulmonary artery smooth muscle cell (PASMC) proliferation this is still largely unknown. G9a is a key enzyme for histone H3 dimethylation at position lysine-9. In this study, we have investigated the function of G9a in ovine foetal PASMC proliferation, migration and contractility. MATERIAL AND
methodsCell proliferation was measured by cell counting and BrdU incorporation assay and cell cycle analysis was performed by flow cytometry. Expression of cell cycle-related genes was determined by real-time PCR and the wound-healing scratch assay was used to measure cell migration. A gel contraction assay was used to determine contractility of foetal PASMCs. Global DNA methylation was measured by liquid chromatography-mass spectroscopy.
resultsInhibition of G9a by its inhibitor BIX-01294 reduced proliferation of foetal PASMCs and induced cell cycle arrest in G(1) phase. This was accompanied by increased p21 expression, but not p53 and other cell cycle-related genes. Treatment of foetal PASMCs with BIX-01294 inhibited platelet-derived growth factor-induced cell proliferation and migration. Contractility of foetal PASMCs was also markedly inhibited by BIX-01294. Expression of calponin and ROCK-II proteins was reduced by BIX-01294 in a dose-dependent manner and BIX-01294 significantly increased global methylation level in the foetal PASMCs.
conclusionOur results demonstrate for the first time that histone lysine methylation is involved in cell proliferation, migration, contractility and global DNA methylation in foetal PASMCs. Further understanding of this mechanism may provide insight into proliferative vascular disease in the lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.